[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):548-551. doi: 10.3760/cma.j.issn.0253-2727.2017.06.017.

[Article in Chinese]

Authors

W Liu, J Li, W Y Huang, H Liu, Z J Li, R Lv, S H Deng, M W Fu, W W Sui, T Y Wang, L G Qiu, D H Zou¹

Affiliation

¹ Department of Lymphoma and Myeloma, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China.

PMID: 28655103
PMCID: PMC7342966
DOI: 10.3760/cma.j.issn.0253-2727.2017.06.017

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Etoposide
Humans
Lymphoma*
Prednisone
Rituximab
Vincristine

Substances

Rituximab
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

EPOCH protocol

Grants and funding

基金项目：国家科技支撑计划（2014BAI09B12）；国家自然科学基金（81370632、81200395）